Investor News

Webcast Event: Jefferies 2018 Global Healthcare Conference, June 5th at 8:30 a.m. New York City time

Webcast available here.

Result of AGM

2018 Poll Result

Indivior Enters into Settlement with Par Pharmaceutical in Patent Infringement Case

Slough, UK, May 14, 2018 – Indivior PLC (LON: INDV) (“Indivior” or the “Company”) today…

Webcast Event: Q1 2018 Financial Results

Listen to the live webcast here.

Presentation: Q2 2018 Conferences & Investor Meeting Handout

PDF Presentation can be downloaded here.

Indivior Q1 2018 Results On Track. FY 2018 Guidance Reconfirmed. Encouraging SUBLOCADE™ Launch.

Indivior Announces New Drug Submission to Health Canada for SUBLOCADE™ (Buprenorphine Extended-Release) Injection for the Treatment of Moderate to Severe Opioid Use Disorder

Health Canada Grants Priority Review Designation for SUBLOCADE™ Slough, UK and Richmond, VA, 20 April…

Patient-Reported Outcomes Data on SUBLOCADEᵀᴹ (Buprenorphine Extended-Release) Injection to be Presented as Late-Breaker at American Society of Addiction Medicine (ASAM) 49ᵗʰ Annual Conference

Data Show High Medication Satisfaction and Positive Health Outcomes in People with Moderate to Severe…

Indivior to Announce First Quarter 2018 Results on May 2nd and Host Conference Call

Slough, UK, and Richmond, VA, 11 April 2018 – Indivior PLC (LON: INDV) today announced…

Indivior Files Complaints Asserting New SUBOXONE® Film Patent Against ANDA-filers

Slough, UK, 5 April 2018 – Indivior PLC (LON: INDV) (“Indivior” or the “Company”) today…